Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence

被引:0
|
作者
Timothy Edward Kute
Jan Grøndahl-Hansen
Si-Ming Shao
Rena Long
Greg Russell
Nils Brünner
机构
[1] Bowman Gray School of Medicine,Department of Pathology
[2] Rigshospitalet,Finsen Laboratory
[3] Bowman Gray School of Medicine,Department of Public Health Sciences Section on Biostatistics
来源
关键词
prognostic markers; proteases; protease inhibitors; node negative;
D O I
暂无
中图分类号
学科分类号
摘要
Prognostic factors are highly needed to divide node negative breast cancer patients into groups of low versus high risk of recurrence and death. In order to invade and spread, cancer cells must degrade extracellular matrix proteins. Accordingly, tumor levels of molecules involved in this degradation might be associated with patient outcome. Previous work has demonstrated that high levels of the aspartyl protease cathepsin D in breast cancer are associated with a poor prognosis and similar findings have been reported for molecules involved in the urokinase pathway of plasminogen activation. Interactions between different protease systems have been described and data suggest that several proteolytic enzymes may be operable at the same time in a tumor. In the present study we measured cathepsin D (n=162), uPA (n=116), uPAR (n=109) and PAI-1 (n=135) in tumor cytosols obtained from a population of node negative breast cancer patients. A significant correlation was found between levels of uPA, uPAR, and PAI-1. Levels of cathepsin D were directly related to levels of uPA and uPAR. With a median observation time of 4.81 years, univariate survival analyses showed that high levels of uPA and cathepsin D significantly predicted a shorter disease free survival, while only high levels of cathepsin D were able to significantly predict a shorter overall survival. Tumor levels of uPAR and PAI-1 gave mixed results depending on the cut-off point choosen. Interestingly, multivariate analysis demonstrated that PAI-1 and cathepsin D were independent significant prognostic indicators for disease-free survival while only cathepsin D was helpful in overall survival. The five year relapse rate of patients with low PAI-1 and low cathepsin D was 13% while patients who had greater than the median value for both of these molecules had a 5 year relapse rate of 40%. These data would indicate that at least two different protease systems are active in spread of node negative breast cancer and that measurement of these molecules may aid in the decisions to be made when offering adjuvant treatment to these patients.
引用
收藏
页码:9 / 16
页数:7
相关论文
共 50 条
  • [1] Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence
    Kute, TE
    Grondahl-Hansen, J
    Shao, SM
    Long, R
    Russell, G
    Brünner, N
    BREAST CANCER RESEARCH AND TREATMENT, 1998, 47 (01) : 9 - 16
  • [2] Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients
    GrondahlHansen, J
    Christensen, IJ
    Briand, P
    Pappot, H
    Mouridsen, HT
    BlichertToft, M
    Dano, K
    Brunner, N
    CLINICAL CANCER RESEARCH, 1997, 3 (02) : 233 - 239
  • [3] Low risk of recurrence in breast cancer with negative sentinel node
    Hildebrandt, Malene Grubbe
    Bartram, Peter
    Bak, Martin
    Hoilund-Carlsen, Mette
    Petersen, Henrik
    Grupe, Peter
    Knoop, Ann
    Ryttov, Nis
    Hoilund-Carlsen, Poul Flemming
    DANISH MEDICAL BULLETIN, 2011, 58 (04)
  • [4] Comparison of the tumor associated proteases cathepsin D (CATH D) and urokinase-type plasminogen activator (uPA) in cytosols of human breast cancer patients
    Liebert, A
    Quietzsch, D
    Beier, L
    ANTICANCER RESEARCH, 1999, 19 (4A) : 2571 - 2576
  • [5] Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L
    Thomssen, C
    Oppelt, P
    Jänicke, F
    Ulm, K
    Harbeck, N
    Höfler, H
    Kuhn, W
    Graeff, H
    Schmitt, M
    ANTICANCER RESEARCH, 1998, 18 (3C) : 2173 - 2180
  • [6] FLOW-CYTOMETRY IDENTIFIES A GROUP OF NODE-NEGATIVE BREAST-CANCER PATIENTS WITH LOW-RISK OF RECURRENCE
    CLARK, GM
    DRESSLER, LG
    OWENS, MA
    MCGUIRE, WL
    BREAST CANCER RESEARCH AND TREATMENT, 1988, 12 (01) : 132 - 132
  • [7] Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1
    Jänicke, F
    Prechtl, A
    Thomssen, C
    Harbeck, N
    Meisner, C
    Untch, M
    Sweep, CGJF
    Selbmann, HK
    Graeff, H
    Schmitt, M
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (12) : 913 - 920
  • [8] Elucidation of low molecular weight inhibitors of plasminogen activator inhibitor type 1.
    Lewis, RD
    Pryor, KE
    Tachias, K
    Duncan, DF
    Lawrence, CM
    Fandrick, DF
    Anderson, SM
    Bergum, PW
    Semple, JE
    Madison, EL
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U24 - U24
  • [9] Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity
    Agren, Anna
    Wiman, Bjoern
    Schulman, Sam
    BLOOD COAGULATION & FIBRINOLYSIS, 2007, 18 (07) : 657 - 660
  • [10] Increased concentration of tissue plasminogen activator plasminogen activator inhibitor type 1 complex (TPA-PAI-1) and urokinase plasminogen activator (UPA) in cytosols of early stage of malignant breast cancer.
    GarciaManzano, A
    GonzalezLlaven, J
    RicoGonzalez, T
    BaselisCastanon, JC
    GarciaCebada, M
    BahenaResendiz, P
    deLeon, LD
    BLOOD, 1997, 90 (10) : 3131 - 3131